229 related articles for article (PubMed ID: 28975710)
1. Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression.
Gebara MA; DiNapoli EA; Kasckow J; Karp JF; Blumberger DM; Lenze EJ; Mulsant BH; Reynolds CF
Int J Geriatr Psychiatry; 2018 Feb; 33(2):e330-e335. PubMed ID: 28975710
[TBL] [Abstract][Full Text] [Related]
2. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.
Lenze EJ; Mulsant BH; Blumberger DM; Karp JF; Newcomer JW; Anderson SJ; Dew MA; Butters MA; Stack JA; Begley AE; Reynolds CF
Lancet; 2015 Dec; 386(10011):2404-12. PubMed ID: 26423182
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.
Han C; Wang SM; Kwak KP; Won WY; Lee H; Chang CM; Tang TC; Pae CU
J Psychiatr Res; 2015; 66-67():84-94. PubMed ID: 26013203
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study.
Ozaki N; Otsubo T; Kato M; Higuchi T; Ono H; Kamijima K;
Psychiatry Clin Neurosci; 2015 Jan; 69(1):34-42. PubMed ID: 24965202
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
Nelson JC; Thase ME; Bellocchio EE; Rollin LM; Eudicone JM; McQuade RD; Marcus RN; Berman RM; Baker RA
Int Clin Psychopharmacol; 2012 May; 27(3):125-33. PubMed ID: 22466058
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
Cheon EJ; Lee KH; Park YW; Lee JH; Koo BH; Lee SJ; Sung HM
J Clin Psychopharmacol; 2017 Apr; 37(2):193-199. PubMed ID: 28129308
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
[TBL] [Abstract][Full Text] [Related]
9. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
[TBL] [Abstract][Full Text] [Related]
10. Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial.
Hsu JH; Mulsant BH; Lenze EJ; Sanches M; Karp JF; Reynolds CF; Blumberger DM
J Clin Psychiatry; 2018 Jun; 79(4):. PubMed ID: 29924506
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials.
Ji M; Feng J; Liu G
PLoS One; 2024; 19(4):e0299020. PubMed ID: 38669232
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder.
Kamijima K; Yasuda M; Yamamura K; Fukuta Y
Curr Med Res Opin; 2018 Dec; 34(12):2105-2112. PubMed ID: 30173568
[TBL] [Abstract][Full Text] [Related]
13. A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole.
Reimherr FW; Martin ML; Eudicone JM; Marchant BK; Tran QV; Pikalov A; Marcus RN; Berman RM; Carlson BX
J Clin Psychopharmacol; 2010 Jun; 30(3):300-5. PubMed ID: 20473067
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
[TBL] [Abstract][Full Text] [Related]
15. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
Stewart TD; Hatch A; Largay K; Sheehan JJ; Marler SV; Berman RM; Nelson JC
J Affect Disord; 2014 Jun; 162():20-5. PubMed ID: 24766999
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
[TBL] [Abstract][Full Text] [Related]
17. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
Bauer M; Dell'osso L; Kasper S; Pitchot W; Dencker Vansvik E; Köhler J; Jørgensen L; Montgomery SA
J Affect Disord; 2013 Oct; 151(1):209-19. PubMed ID: 23810357
[TBL] [Abstract][Full Text] [Related]
18. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.
Mischoulon D; Hylek L; Yeung AS; Clain AJ; Baer L; Cusin C; Ionescu DF; Alpert JE; Soskin DP; Fava M
J Affect Disord; 2017 Jan; 208():6-14. PubMed ID: 27736689
[TBL] [Abstract][Full Text] [Related]
19. Low- and high-dose aripiprazole augmentation and plasma levels of homovanillic acid in major depressive disorder: A randomized, open-label study.
Horikoshi S; Miura I; Ichinose M; Yamamoto S; Ito M; Watanabe K; Kanno-Nozaki K; Kaneko H; Yabe H
Hum Psychopharmacol; 2019 May; 34(3):e2696. PubMed ID: 31044463
[TBL] [Abstract][Full Text] [Related]
20. General Predictors and Moderators of Depression Remission: A VAST-D Report.
Zisook S; Johnson GR; Tal I; Hicks P; Chen P; Davis L; Thase M; Zhao Y; Vertrees J; Mohamed S
Am J Psychiatry; 2019 May; 176(5):348-357. PubMed ID: 30947531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
